 Home > Active Ingredient News > Drugs Articles > IL-36R monoclonal antibody reported for the market, Boehringer Ingelheim's first innovative drug of its kind

IL-36R monoclonal antibody reported for the market, Boehringer Ingelheim's first innovative drug of its kind

 Last Update: 2021-12-06
 Source: Internet
 Author: User

Tags

endocrine system diseases

horizant drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

introduction

On November 18, 2021, the Center for Drug Evaluation undertook the listing application of Boehringer Ingelheim's Class 1 biological product Spesolimab injection (Spesolimab)
.

(Source: CDE official website)

Spesolimab Spesolimab is an IL-36R (interleukin-36 receptor) monoclonal antibody that can block the effect of IL-36R receptor.
It is the first treatment of its kind under development
.

Studies have confirmed that it can significantly improve the symptoms of Generalized Pustular Psoriasis (GPP)

Spesolimab IL-36R Boehringer Ingelheim

Boehringer Ingelheim has substantially increased its R&D investment since 2020, aiming to develop innovative drugs and therapies for diseases that cannot be effectively treated
.

In 2020, Boehringer Ingelheim's total R&D expenditure will reach 3.
7 billion euros

At present, Boehringer Ingelheim has a product pipeline consisting of more than 40 preclinical drugs and more than 15 clinical stage drugs covering cardiovascular diseases, tumors, respiratory diseases, immunity, central nervous system diseases, retinal diseases and other therapeutic fields
.

(Pipeline source: Boehringer Ingelheim official website)

Reference source:

Reference source: Reference source:

[1] CDE official website

[2] boehringer-ingelheim.

com

[2] boehringer-ingelheim.
com

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Tirzepatide Lyophilized powder Vial 5mg 10mg 15mg 20mg 30mg customize 99% Purity with third side checking report

CAS No.: 2023788-19-2

Pharmacy Grade

$50-60/UNIT FOB

Wight loss Lyophilized Semaglutide Petide powder CAS 910463-68-2 with 99.9% purity

CAS No.: 910463-68-2

Pharmacy Grade

$140-175/G FOB

High Quality (E,E,E,E)-Squalene CAS NO 111-02-4 GMP ISO9001 EP Pharma grade Manufacture

CAS No.: 111-02-4

EP Pharma grade

$400-405/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.